AU2022283025A1 - Diagnostic for sepsis endotypes and/or severity - Google Patents

Diagnostic for sepsis endotypes and/or severity Download PDF

Info

Publication number
AU2022283025A1
AU2022283025A1 AU2022283025A AU2022283025A AU2022283025A1 AU 2022283025 A1 AU2022283025 A1 AU 2022283025A1 AU 2022283025 A AU2022283025 A AU 2022283025A AU 2022283025 A AU2022283025 A AU 2022283025A AU 2022283025 A1 AU2022283025 A1 AU 2022283025A1
Authority
AU
Australia
Prior art keywords
endotype
signature
fech
lgals3bp
efna1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022283025A
Other languages
English (en)
Inventor
Arjun BAGHELA
Gabriela Cohen Freue
Robert E. Hancock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of AU2022283025A1 publication Critical patent/AU2022283025A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
AU2022283025A 2021-05-25 2022-05-25 Diagnostic for sepsis endotypes and/or severity Pending AU2022283025A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192746P 2021-05-25 2021-05-25
US63/192,746 2021-05-25
PCT/CA2022/050831 WO2022246553A1 (en) 2021-05-25 2022-05-25 Diagnostic for sepsis endotypes and/or severity

Publications (1)

Publication Number Publication Date
AU2022283025A1 true AU2022283025A1 (en) 2024-01-18

Family

ID=84229117

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022283025A Pending AU2022283025A1 (en) 2021-05-25 2022-05-25 Diagnostic for sepsis endotypes and/or severity

Country Status (7)

Country Link
US (1) US20240254557A1 (enExample)
EP (1) EP4352250A4 (enExample)
JP (1) JP2024520049A (enExample)
CN (1) CN117751195A (enExample)
AU (1) AU2022283025A1 (enExample)
CA (1) CA3221576A1 (enExample)
WO (1) WO2022246553A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148050A2 (en) * 2023-01-04 2024-07-11 Ampel Biosolutions, Llc Longitudinal gene expression analysis of inflammatory skin diseases
EP4766855A1 (en) * 2023-08-22 2026-07-01 Ramot at Tel-Aviv University Ltd. SYSTEMIC RESISTANCE AND INFLAMMATION MARKERS AND THEIR USES
WO2025090733A1 (en) * 2023-10-27 2025-05-01 Sanofi Identifying disease subtypes
CN118389664A (zh) * 2024-04-24 2024-07-26 南方医科大学深圳医院 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法
CN118621011B (zh) * 2024-06-18 2025-08-29 广东医科大学附属医院 circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用
CN120939040A (zh) * 2025-10-20 2025-11-14 四川省医学科学院·四川省人民医院 GYG1 siRNA在制备治疗脓毒症的药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20110076685A1 (en) 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110312521A1 (en) 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
EP2834638B1 (en) 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
EP3013985A4 (en) 2013-06-28 2017-07-19 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
WO2015117204A1 (en) * 2014-02-06 2015-08-13 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
CA2942577A1 (en) 2014-03-14 2015-09-17 Robert E. W. Hancock Diagnostic for sepsis
CN107532214B (zh) 2015-03-12 2021-08-31 斯坦福大学托管董事会 用于败血症诊断的方法
GB201518597D0 (en) * 2015-10-20 2015-12-02 Univ Liverpool Detection of bacterial infection
US11104953B2 (en) * 2016-05-13 2021-08-31 Children's Hospital Medical Center Septic shock endotyping strategy and mortality risk for clinical application
KR101929772B1 (ko) * 2016-11-02 2018-12-17 연세대학교 산학협력단 패혈증 진단을 위한 정보를 제공하는 방법 및 이를 이용한 키트
WO2018146162A1 (en) * 2017-02-07 2018-08-16 Academisch Medisch Centrum Molecular biomarker for prognosis of sepsis patients
US12571044B2 (en) * 2018-02-27 2026-03-10 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
US20210388443A1 (en) * 2018-11-05 2021-12-16 Institute For Systems Biology Sepsis biomarker panels and methods of use

Also Published As

Publication number Publication date
EP4352250A4 (en) 2026-07-01
CA3221576A1 (en) 2022-12-01
US20240254557A1 (en) 2024-08-01
CN117751195A (zh) 2024-03-22
EP4352250A1 (en) 2024-04-17
WO2022246553A1 (en) 2022-12-01
JP2024520049A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
US20240401107A1 (en) Methods and systems for processing a nucleic acid sample
AU2020201564B2 (en) Diagnostic for sepsis
US20240254557A1 (en) Diagnostic for sepsis endotypes and/or severity
US11091809B2 (en) Molecular diagnostic test for cancer
US10260097B2 (en) Method of using a gene expression profile to determine cancer responsiveness to an anti-angiogenic agent
Rodriguez et al. Viral genomic, metagenomic and human transcriptomic characterization and prediction of the clinical forms of COVID-19
AU2015213486A1 (en) Biomarker signature method, and apparatus and kits therefor
AU2012261820A1 (en) Molecular diagnostic test for cancer
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
CA3204787A1 (en) Methods to detect and treat a fungal infection
HK1237382A1 (en) Diagnostic for sepsis